AstraZeneca PLC (NASDAQ:AZN) Q4 2023 Earnings Conference Call February 8, 2024 6:45 AM ET

Company Participants

Andy Barnett - Head, IR

Pascal Soriot - CEO

Aradhana Sarin - CFO

David Fredrickson - EVP, Oncology Business

Susan Galbraith - EVP, Oncology R&D

Ruud Dobber - EVP, BioPharmaceuticals Business

Sharon Barr - EVP, BioPharmaceuticals R&D

Marc Dunoyer - CEO, Alexion

Iskra Reic - EVP of Vaccines & Immune Therapies

Conference Call Participants

James Gordon - JP Morgan

Emily Field - Barclays

Matthew Weston - UBS

Andrew Baum - Citi

Peter Welford - Jefferies

Mark Purcell - Morgan Stanley

Simon Baker - Redburn

Tim Anderson - Wolfe Research

Luisa Hector - Berenberg

Eric Le Berrigaud - Stifel

Gonzalo Artiach - ABG

Andy Barnett

Well, a warm welcome everybody to AstraZeneca's Fourth Quarter and Full Year '23 Results Presentation Conference Call and Webcast for Investors and Analysts. I'm Andy Barnett, Head of Investor Relations. And before I hand over to Pascal and Members of the Executive Team, I'd like to cover some important housekeeping points.

Firstly, as I'm probably sure you realize all the materials are already on our website for your review. Here's our forward-looking statement, which I'd encourage you to take the time to read. We'll be making comments on our performance using constant exchange rates, or CER, core financial numbers and other non-GAAP measures. And non-GAAP to GAAP reconciliation is contained within the results announcement that you all have seen. All numbers quoted are in millions of U.S dollars unless otherwise stated.

This slide shows the agenda for today's call, following up our prepared remarks, we’ll open the line for questions. Of course, if you want to raise -- ask a question in the room, raise your hands, there'll be roving mics for those online, please use the zoom function to raise your hand. As usual, we'll try and get to as many questions as we can through the course of the call. But if you limit the number of questions you ask at once, it'll give others a fair chance to participate.

And with that, Pascal, I'm going to hand over to you.

Pascal Soriot

Thank you, Andy. Good morning, everybody. And welcome to this London Stock Exchange, where we are celebrating our 25th anniversary as a company, merging Astra from Sweden and Zeneca from the UK, quite a number of years ago. But I want to start my talk with this slide. And this slide is important because I want to recognize or celebrate the fact that not only it's our 25th anniversary, but importantly, we actually did achieve the goal we set ourselves 10 years ago to reach $45 billion sales in 2023.